Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Enterprise Value: 2009-2025

Historic Enterprise Value for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Sep 2025 value amounting to $9.1 billion.

  • Madrigal Pharmaceuticals' Enterprise Value rose 152.50% to $9.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 billion, marking a year-over-year increase of 662.83%. This contributed to the annual value of $5.8 billion for FY2024, which is 47.53% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Enterprise Value of $9.1 billion as of Q3 2025, which was up 53.87% from $5.9 billion recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Enterprise Value's 5-year high stood at $9.1 billion during Q3 2025, with a 5-year trough of $958.4 million in Q3 2022.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Enterprise Value value was $4.3 billion (recorded in 2024), while the average stood at $5.0 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 31.51% in 2021, then surged by 290.81% in 2022.
  • Madrigal Pharmaceuticals' Enterprise Value (Quarterly) stood at $1.2 billion in 2021, then surged by 290.81% to $4.6 billion in 2022, then decreased by 14.58% to $3.9 billion in 2023, then soared by 47.53% to $5.8 billion in 2024, then skyrocketed by 152.50% to $9.1 billion in 2025.
  • Its last three reported values are $9.1 billion in Q3 2025, $5.9 billion for Q2 2025, and $6.5 billion during Q1 2025.